T cell binding proteins

By designing an optimized binding protein structure, preferential binding of CD8+ T cells, reducing regulatory T cell junction, improving the killing efficacy and safety of tumor cells, solving the problems of high cytokine release and short half-life in the existing technology, and achieving high efficiency tumor treatment.

CN118974091APending Publication Date: 2024-11-15ASTRAZENECA AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032014.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-11
Filing Date
2023-04-06
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing CD3-based bispecific T cell conjugates have problems with high cytokine release syndrome and short half-life when treating tumors, and the cell lytic activity of CD8 T cells is reduced, making it difficult to effectively reduce off-target effects.

Method used

A binding protein was designed, including two tumor-associated antigen binding sites, T cell receptor binding sites and T cell costimulatory molecule binding sites, which preferentially binds CD8+ T cells to reduce regulatory T cells with The ligation and the design of specific domain locations and linker improves cell lytic activity and reduces cytokine release.

Benefits of technology

It achieves efficient tumor cell killing in vitro and in vivo, reduces the incidence of cytokine release syndrome, improves the activity and cell lysis capacity of CD8 T cells, and enhances the safety and effectiveness of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118974091A_ABST
    Figure CN118974091A_ABST
Patent Text Reader

Abstract

The present disclosure relates generally to binding proteins comprising antigen binding sites, T cell receptor binding sites, and T cell costimulatory molecule binding sites. The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating disorders or conditions using such binding proteins.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 63 / 329,583, filed on April 11, 2022, the contents of which are hereby incorporated herein by reference. Technical Field

[0003] The present disclosure generally relates to binding proteins, which contain antigen binding sites, T cell receptor binding sites and T cell costimulatory molecule binding sites. The present disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The present disclosure further relates to methods for treating disorders or diseases using such binding proteins.

[0004] Sequence Listing Statement

[0005] A computer readable form of the sequence listing is submitted with this application by electronic submission and is incorporated by reference in its entirety into this application. The sequence listing is contained in a file created on March 14, 2023, with the file name "21-0750-WO.xml" and a file size of 71,648 bytes. Background of the Invention

[0007] Recruiting T cells' cytotoxic activity to destroy tumor cells is a valuable but complex strategy for cancer treatment. CD3-based bispecific T cell engagers (TCEs) have been under development as cancer therapeutics over the past 30 years. TCEs simultaneously bind to tumor-associated antigens (TAAs) and cluster of differentiation 3 (CD3) on T cells to form a T cell receptor (TCR)-independent artificial immune synapse, circumventing human leukocyte antigen (HLA) restriction and inducing T cell activation and cytolysis of tumor cells.

[0008] The first generation of TCEs were simple bispecific T cell engagers (BiTEs) consisting of two tandem single-chain variable fragments (scFv) that included a strong CD3 binding arm and a TAA binding domain. To date, there is only one Food and Drug Administration-approved BiTE, blinatumomab, which targets CD3 (using the Orthoclone OKT3 antibody) and cluster of differentiation 19 (CD19). During the development of BiTEs, strong in vitro cytolytic activity was observed, which led to interest in their potential use in the treatment of cancer. However, the unexpected high cytokine release syndrome (CRS) observed in the clinic has somewhat undermined this excitement. (Teachey et al., “Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy,” Blood 121:5154-57 (2013)). Another observed disadvantage of the BiTE format is that they exhibit an extremely short half-life and have poor manufacturability (Ellerman, “Bispecific T cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety,” Methods 154:102-17 (2019)).

[0009] The second generation of TCEs includes a fragment crystallizable (Fc) domain that can be modified to extend half-life and impart mutations to eliminate Fc receptor (FcR) binding, and presents improved manufacturability (Vafa et al., "Perspective: Designing T cell Engagers With Better Therapeutic Windows," Front Oncol. [Oncology Frontier] 10: 446 (2020)). However, these molecules still include a high-affinity CD3 binding domain, which is associated with the induction of neurotoxicity and CRS in the clinic. Recently, efforts have been focused on developing CD3 binding domains with reduced affinity, hoping to maintain effective T cell activation while significantly reducing related cytokine release (Trinklein et al., "Efficient tumor killing and minimal cytokine release with novel T cell agonist bispecific antibodies," MAbs 11: 639-52 (2019)).

[0010] Importantly, both CD3-based BiTEs and the novel immunoglobulin G (IgG) format of TCEs bind and activate both cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) T cells, potentially engaging adverse T cells such as regulatory T cells (Tregs), which have been shown to potentially reduce the cytolytic activity of CD8 T cells (Duell et al., “Frequency of regulatory T cells determines the outcome of the T cell-engaging antibody blinatumomab in patients with B-precursor ALL,” Leukemia 31:2181-90 (2017)).

[0011] While T cell engager molecules offer promise, this therapeutic approach has thus far faced challenges. There is a need in the art for improved T cell engaging proteins with increased activity and reduced off-target effects. Summary of the invention

[0012] The present disclosure provides a binding protein comprising four polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site and a T cell co-stimulatory molecule binding site, wherein the first and second polypeptide chains have a structure represented by the following formula: L -C L And the third polypeptide chain has a structure represented by the following formula: H1 -C H1- V H2 -Fc and the fourth polypeptide chain has a structure represented by the following formula: H1 -C H1 -V H3 -Fc, where: V L It is the immunoglobulin light chain variable domain that specifically binds to tumor-associated antigens; V H1 It is an immunoglobulin heavy chain variable domain that specifically binds to tumor-associated antigens; C L It is the constant domain of immunoglobulin light chain that specifically binds to tumor-associated antigens; C H1 It is the constant domain of the immunoglobulin CH1 heavy chain that specifically binds to tumor-associated antigens; V H2 V is the heavy chain variable domain that specifically binds to the T cell receptor; H3 is a heavy chain variable domain that specifically binds to T cell co-stimulatory molecules; and Fc is C H2 and C H3 Immunoglobulin heavy chain constant domain.

[0013] The present invention also provides a binding protein, which comprises four polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site and a T cell co-stimulatory molecule binding site, wherein two polypeptide chains have a structure represented by the following formula: L -C L And the two polypeptide chains have the structure represented by the following formula: III-V H1 -C H1- V H2 -Fc-II2; wherein: V L It is the immunoglobulin light chain variable domain that specifically binds to tumor-associated antigens; V H1 It is an immunoglobulin heavy chain variable domain that specifically binds to tumor-associated antigens; C L It is the constant domain of immunoglobulin light chain that specifically binds to tumor-associated antigens; C H1 It is the constant domain of the immunoglobulin CH1 heavy chain that specifically binds to tumor-associated antigens; V H2 It is the heavy chain variable domain that specifically binds to the T cell receptor; Fc is C H2 and C H3An immunoglobulin heavy chain constant domain; III1 and II2 are each independently a heavy chain variable domain that specifically binds to a T cell co-stimulatory molecule or are absent; wherein at least one of III1 and II2 is a heavy chain variable domain that specifically binds to a T cell co-stimulatory molecule.

[0014] The present invention also provides a binding protein, which comprises four polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site and a T cell co-stimulatory molecule binding site, wherein two polypeptide chains have a structure represented by the following formula: III-V L -C L -II2; and the two polypeptide chains have a structure represented by the following formula: V H1 -C H1- V H2 -Fc; where: V L It is the immunoglobulin light chain variable domain that specifically binds to tumor-associated antigens; V H1 It is an immunoglobulin heavy chain variable domain that specifically binds to tumor-associated antigens; C L It is the constant domain of immunoglobulin light chain that specifically binds to tumor-associated antigens; C H1 It is the constant domain of the immunoglobulin CH1 heavy chain that specifically binds to tumor-associated antigens; V H2 It is the heavy chain variable domain that specifically binds to the T cell receptor; Fc is C H2 and C H3 An immunoglobulin heavy chain constant domain; III1 and II2 are each independently a heavy chain variable domain that specifically binds to a T cell co-stimulatory molecule or are absent; wherein at least one of III1 and II2 is a heavy chain variable domain that specifically binds to a T cell co-stimulatory molecule.

[0015] The present invention also provides a binding protein, which comprises three polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site and a T cell co-stimulatory molecule binding site, wherein the first polypeptide chain has a structure represented by the following formula: L -C L ; and the second polypeptide chain has a structure represented by the following formula: V H1 -C H1- V H2 -Fc; and the third polypeptide chain has a structure represented by the following formula: V H1 -V H3 -Fc; where: V L It is the immunoglobulin light chain variable domain that specifically binds to tumor-associated antigens; V H1 It is an immunoglobulin heavy chain variable domain that specifically binds to tumor-associated antigens; C L It is the constant domain of immunoglobulin light chain that specifically binds to tumor-associated antigens; CH1 It is the constant domain of the immunoglobulin CH1 heavy chain that specifically binds to tumor-associated antigens; V H2 V is the heavy chain variable domain that specifically binds to the T cell receptor; H3 is a heavy chain variable domain that specifically binds to T cell co-stimulatory molecules; and Fc is C H2 and C H3 Immunoglobulin heavy chain constant domain.

[0016] The present invention also provides a binding protein, which comprises four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise (a) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3; (b) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 4; (c) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 9, and SEQ ID NO: 10; (d) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 11, and SEQ ID NO: 12; (e) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 13, and SEQ ID NO: 14; (f) amino acids of the sequences of SEQ ID NO: 1 and SEQ ID NO: 19; (g) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 22, and SEQ ID NO: 23; (h) amino acids of the sequences of SEQ ID NO: 29 and SEQ ID NO: 30; (i) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 24, and SEQ ID NO: 25; NO:31 and SEQ ID NO:32; (j) amino acids of SEQ ID NO:33 and SEQ ID NO:34; (k) amino acids of SEQ ID NO:35 and SEQ ID NO:36; (l) amino acids of SEQ ID NO:37 and SEQ ID NO:38; (m) amino acids of SEQ ID NO:39 and SEQ ID NO:40; (n) amino acids of SEQ ID NO:41 and SEQ ID NO:42; or (o) amino acids of SEQ ID NO:45 and SEQ ID NO:54.

[0017] The present invention also provides a binding protein comprising three polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise (p) amino acids of the sequences of SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45; or (q) amino acids of the sequences of SEQ ID NO:1, SEQ ID NO:11, and SEQ ID NO:12. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] The accompanying drawings are included to provide a further understanding of the methods and compositions of the present disclosure, and are incorporated in and constitute a part of the present disclosure. The accompanying drawings illustrate one or more aspects of the present disclosure, and together with the description serve to explain the principles and operations of the present disclosure.

[0019] Figure 1 Representative binding protein forms of the present disclosure are described, including two binding sites for tumor-associated antigens (TAA), one binding site for T cell receptors (TCR) on T cells, and one binding site for T cell co-stimulatory molecules. After tumor-specific proteases are cleaved at the designated sites, the Fc domain is released, and the T cells are activated by TCR binding and activation of co-stimulatory receptors.

[0020] Figures 2A to 2B The structures of binding proteins evaluated in different in vitro assays are illustrated. Figure 2A MCAZ 6.9 binding proteins including a protease cleavage site are described. Figure 2B MCAZ 6.10 binding proteins including a protease cleavage site are described.

[0021] Figures 3A to 3C Shown is a line graph depicting the evaluation of MCAZ 6.9 and MCAZ 6.10 binding proteins for in vitro cell lysis on CD20+ B cell lines. The EC50s for both MCAZ 6.9 and MCAZ 6.10 for each cell line are shown. Figure 3A Cytolytic assessment using Daudi cells and purified pan T cells is described. Figure 3B Cytolytic assessment using Ramos cells and purified pan T cells is illustrated. Figure 3C Cytolysis assessment using Raji cells and PBMCs is described.

[0022] Figures 4A to 4B Shown are line graphs depicting the percentage of surface CD25+ cells using Daudi cells as a means of analyzing CD4 and CD8 T cell activation profiles. Figure 4A Results for MCAZ 6.9 binding protein are shown. Figure 4BResults for MCAZ6.10 binding protein are shown.

[0023] Figures 5A to 5B Shown is a line graph depicting the percentage of surface CD25+ cells using Ramos cells.CD25+ assessment was used as a means to analyze the activation profile of CD4 and CD8 T cells. Figure 5A Results for MCAZ 6.9 binding protein are shown. Figure 5B Results for MCAZ 6.10 binding protein are shown.

[0024] Figure 6 Shown is a line graph depicting the percentage of surface CD25+ cells using Raji cells as a means of analyzing CD4 and CD8 T cell activation profiles.

[0025] Figures 7A to 7C The in vitro cytolysis and T cell activation profiles induced by the CD20 T cell MCAZ 88 binding protein are shown. Fig. 7A Representative structures of MCAZ 88-binding proteins are shown. Figure 7B Shown is the induction of MCAZ 88 by cytolysis evaluated on the Raji cell line (CD20+, 85371 antigens / cell). Figure 7C CD4 and CD8 T cell activation profiles assessed by measuring the % of surface CD25+ cells are shown.

[0026] Fig. 8A This is a schematic diagram of MCAZ 7.5 and MCAZ 89. Figures 8B to 8C Shown is a bar graph illustrating non-specific CD4 and CD8 T cell activation in solution as assessed by flow cytometry for CD25+ status. Binding proteins shown from top to bottom in the legend are depicted from left to right along the x-axis. Figure 8B Non-specific CD8 activation is shown. Figure 8C Nonspecific CD4 activation is shown.

[0027] Figures 9A to 9B Shown are bar graphs illustrating non-specific CD8 and CD4 T cell activation in plate-adsorbed antibodies as assessed by flow cytometry detection of CD25+ surface expression. Fig. 9A Non-specific CD8 activation is shown. Binding proteins shown from top to bottom in the legend are depicted from left to right along the x-axis. Fig. 9B Nonspecific CD4 activation is shown.

[0028] Figures 10A to 10E The in vitro cytolysis and T cell activation profiles induced by the uncleavable binding protein are shown. Fig. 10A The structure of the MCAZ 7.1 binding protein is shown. Fig. 10BThe structure of the MCAZ 10.3 binding protein is shown. Fig. 10C Shown is the evaluation of cytolysis on the CD20+ B cell lines Toledo, Oci-LY18 and SU-DHL5 (expressing 12420, 20244 and 27152 CD20 antigens / cell, respectively). Fig. 10D MCAZ 7.1 cytolysis EC50 values ​​for each cell line are shown. Fig.10E CD4 and CD8 T cell activation assessed as % CD25 expressing cells is shown.

[0029] Figures 11A to 11H The in vitro cytolysis, specific and non-specific T cell activation profiles induced by binding proteins with modified linker lengths are shown. Fig.11A The structure of the MCAZ 7.7 binding protein is shown, including an additional linker between the CD20 binding domain and the TCR binding domain. Fig. 11B Shown is the evaluation of cytolysis on the CD20+ Raji B cell line (expressing 85,000 CD20 antigens / cell). Fig. 11C CD4 and CD8 T cell activation profiles assessed as % CD25 expressing cells are shown. Fig.11D Shown are plate binding of binding proteins and addition of 1.5e5 purified T cells in the absence of tumor cells and associated proteases. Non-specific CD8 and CD4 T cell activation levels were assessed by flow cytometry as %CD69+ / CD25+ surface expression. Fig.11E Shown is the structure of the MCAZ 10.1 binding protein with a more rigid CD8 arm by removing the TGGS (SEQ ID NO: 46) linker and the HA tag in addition to removing the cleavable linker. Fig.11F Shown is the assessment of cytolysis on the OCI-Ly18 B cell line. The B cell line was stained for CTV and PBMCs were incubated for 3 days at an E:T ratio of 5:1. % cytolysis was measured by flow cytometry. Fig.11G and 11H CD8 and CD4 T cell activation profiles assessed as % CD25 expressing cells are shown.

[0030] Figures 12A to 12E Evaluation of the effect of CD8 localization on binding proteins is shown. Fig. 12A The structure of the MCAZ 8.71 binding protein is shown. Fig. 12B The structure of the MCAZ 8.81 binding protein is shown. Fig. 12C Shown is the evaluation of cytolysis on the CD20+BRaji cell line (expressing 85000 CD20 antigens / cell). Fig.12D The cytolytic EC50 values ​​for each cell line are shown. Fig.12E CD4 and CD8 T cell activation profiles assessed as % CD25 expressing cells are shown.

[0031] Figures 13A to 13E Evaluation of TCRVHH and CD8 VHH bispecific binding proteins is shown. Fig.13A The structure of the MCAZ8.69 binding protein is shown. Fig. 13B The structure of the MCAZ 8.70 binding protein is shown. Fig. 13C Shown are cytolysis assessed on the CD20+BRaji cell line (expressing 85000 CD20 antigens / cell). Fig.13D The cytolytic EC50 values ​​for each cell line are shown. Fig.13E CD4 and CD8 T cell activation profiles assessed as % CD25 expressing cells are shown.

[0032] Figures 14A to 14B Evaluation of nonspecific T cell activation of various binding proteins is shown. Different concentrations of binding proteins were plate-bound and 1.5e5 purified T cells were added in the absence of tumor cells and associated proteases. After 48 h of incubation, nonspecific ( Fig.14A )CD8 and ( Fig. 14B ) CD4 T cell activation level as %CD69+ / CD25+ surface expression.

[0033] Fig.15A is a schematic diagram of MCAZ 8.71 binding proteins with different Fc regions. Fig. 15B Cytolytic activity of the binding proteins on the OCI-Ly18 B cell line (with PBMCs at an E:T ratio of 5:1) at 72h is shown. Fig. 15C and 15D CD8 and CD4 T cell activation profiles assessed by measuring the % of surface CD25+ T cells are shown.

[0034] Figures 16A to 16C The cytolytic activity of a MCAZ 7.1 variant (TENG0093) with a modified linker is shown. In particular, the variant includes similar linkers on the CD8 and TCRVHH arms, such as Fig.16A This variant has a different spectrum than the broad CD3xCD20 bivalent conjugate. Fig.16A Shown are the structures of modified MCAZ7.1 with different linkers and the broad CD3xCD20 bivalent conjugate used as comparator. Fig. 16B The cytolytic activity of MCAZ 7.1 variants and CD3xCD20 bivalent conjugates on the OCI-Ly18B cell line is shown. Fig. 16CCD4 and CD8 T cell activation profiles assessed as surface expression of CD25 at 72 h are shown.

[0035] Figures 17A to 17F It was shown that MCAZ 7.1 exhibited strong binding to CD8 T cells and induced preferential association of CD20+ tumor cells with CD8 T cells compared to the broad CD3xCD20 bivalent conjugate. Fig.17A Shown are the expression of cytokines in CD20+ tumor B cell lines (OCI-Ly-18), in PBMCs from healthy donors ( Fig. 17B ) purified CD4 and ( Fig. 17C ) MCAZ 7.1 binding profile on CD8 T cells. Fig.17D A magnified image of the CD3xCD20 bivalent conjugate binding to CD8 T cells is shown. Fig.17E ) with MCAZ 7.1 and ( Fig.17F )After incubation with the CD3xCD20 bivalent conjugate, the % of CD8-B cell conjugates and CD4-T cell conjugates were assessed by flow cytometry after staining of CD4 and CD8 T cells.

[0036] Figures 18A to 18F Shown that compared with the extensive CD3+T cell engagement by CD3xCD20 bivalent engagers, MCAZ 7.1 selective engagement of CD8 T cells during cytolysis was associated with significantly lower cytokine release. MCAZ7.1 binding protein and CD3xCD20 bivalent engagers were incubated with OCI-Ly18 B cell line and PBMC at an E:T ratio of 5:1 for 72h. Supernatants were harvested and analyzed by multiple assays to measure the concentrations of the following released proinflammatory cytokines: ( Fig.18A )IL-6, ( Fig.18B )TNF-α、( Fig. 18C )IL-10, Fig.18D )IFN-g, ( Fig.18E )IL-2 and ( Fig.18F )IL-17A.

[0037] Figures 19A to 19B It was shown that MCAZ 7.1 did not induce significant levels of T cell activation and cytokine release compared to the CD3xCD20 bivalent conjugate.Various concentrations of MCAZ 7.1 binding protein and CD3xCD20 bivalent conjugate were plate bound and 1.5e5 PBMCs from healthy donors were added and incubated for 48h. Fig.19A CD4 and CD8 nonspecific T cell activation profiles assessed by flow cytometry for CD25 / CD69+ surface expression levels are shown. Fig.19BA multiplex assay measuring the released pro-inflammatory cytokine concentrations of harvested supernatants is shown.

[0038] Figures 20A to 20B MCAZ 7.1 variant (TENG0093) binding protein and CD3xCD20 bivalent conjugates were shown to induce strong cytolytic activity in 3D spheroid models. CD20+B cell lines (TMD8, 100000 CD20 / cell) expressing GFP were plated in low adhesion plates for 72h to form 3D spheroids. Then, purified pan-T cells were added at an E:T ratio of 15:1, and incubated for 96h in the absence of conjugates, with MCAZ 7.1 variant binding proteins or CD3xCD20 bivalent conjugates. Fig. 20A Representative images of spheroids with MCAZ 7.1 variant binding protein or with CD3xCD20 bivalent conjugate in the absence of binding protein are shown. Fig. 20B Shown are the average % of GFP signal intensity at various concentrations of T cell engager relative to the no-engager control after 96 hours of incubation.

[0039] Fig.21 PK evaluation after a single dose of MCAZ 7.1 binding protein is shown. NSG mice humanized with pan T cells were injected with 0.5 mg / kg of binding protein as indicated, and systemic concentrations of binding protein were measured after 1 h, 6 h, 24 h, 48 h, 72 h, and 168 h.

[0040] Fig. 22 The in vivo efficacy of MCAZ 7.1 binding protein in B cell lymphoma in humanized NSG mouse model is shown. Two days before the start of the study, pan T cells were transplanted into NSG mice. 5e6 OCI-Ly18 CD20+ tumor cell lines were implanted subcutaneously on day 0, and animals were intraperitoneally administered 1 mg / kg of MCAZ 7.1 binding protein or CD3xCD20 bivalent conjugate on day 2, followed by weekly dosing at the same concentration, as indicated by the gray arrows under the X-axis.

[0041] Figures 23A to 23F In vivo cytokine release assessment of MCAZ 7.1 binding protein compared to CD3xCD20 bivalent conjugate in CRS mouse model is shown. Mean + / - SD is plotted for: ( Fig.23A )IL-6, ( Fig. 23B )TNF-α、( Fig.23C )IL-10, Fig.23D )IFN-g, ( Fig.23E )IL-2 and ( Fig.23F )IL-17A.

[0042] Figures 24A to 24H The in vitro activity of MCAZ 7.1 and MCAZ 7.1 variants in binding proteins from non-Hodgkin lymphoma (NHL) donors to PBMCs was shown. B cell killing was assessed on PBMCs from NHL (DLBCL) donors. MCAZ 7.1 variant binding proteins were incorporated into PBMCs at specified concentrations, and after 48h, the % B cells ( Fig.24A , 24C , 24E and 24G). % B cell lysis is presented at different concentrations of the indicated binding proteins for 3 different DLBCL donors ( Fig. 24B , 24D , 24F, 24H). CD4 and CD8 T cell activation profiles were assessed as the % of CD25+ T cells.

[0043] Figures 25A to 25B Representative molecular forms of EGFR TITAN and a broad range of CD3 binders used as comparators are shown.

[0044] Figures 26A to 26B Binding profiles of EGFRTITAN (MCAZ13.8) and a broad range of CD3 comparators to NCIH196 (26A) and MDA-MB231 (26B) are shown.

[0045] Figures 27A to 27B NCIH196-EGFR high in vitro cytotoxicity and T cell activation profiles are shown. 27A shows equivalent cytolytic activity of EGFR TITAN and a broad range of CD3 engagers used as comparators against the NCIH196 tumor cell line. 27B shows the strongly biased CD8 T cell activation profile of EGFR TITAN (MCAZ13.8), as highlighted by %CD25 surface expression on T cells.

[0046] Figures 28A to 28E It was shown that EGFR TITAN (MCAZ13.8) selective engagement of CD8 T cells during cytolysis was associated with significantly lower cytokine release compared to broad CD3+ T cell engagement by the CD3xEGFR bivalent comparator.

[0047] Figures 29A to 29B MDA-MB-231-EGFR showed high in vitro cytotoxicity and T cell activation bias. Fig.29A Equivalent cytolytic activity of EGFRTITAN and a broad CD3 binder used as a comparator was shown against the MDA-MB-231 tumor cell line. Fig.29BA strongly biased CD8 T cell activation profile of EGFR TITAN (MCAZ13.8) is shown, as highlighted by the %CD25 surface expression on T cells.

[0048] Figures 30A to 30E It was shown that EGFR TITAN (MCAZ13.8) selective engagement of CD8 T cells during cytolysis was associated with significantly lower cytokine release compared to broad CD3+ T cell engagement by the CD3xEGFR bivalent comparator.

[0049] Figures 31A to 31B T cell activation is shown. Fig.31A It is shown that the EGFRTITAN (MCAZ 13.8) binding protein does not activate T cells when plate bound at different concentrations. In contrast, the broad CD3 binder used as a comparator induced significant T cell activation at the highest concentration used. Fig.31B It was shown that the lack of T cell activation induced by plate-bound EGFRTITAN (MCAZ 13.8) correlated with the lack of cytokine release.

[0050] Figures 32A to 32C TENG0093 was shown to effectively deplete B cells in fully humanized NSG mice. NSG-SGM3 mice were humanized with human stem cells (CD34+ cells). Fourteen weeks later, animals were treated intraperitoneally with 20 mg / kg of Fc blocker and 16 h later with 1 mg / kg of TENG0093 or CD3xCD20 bivalent conjugates. On day 6 after conjugate treatment, anti-CD19 surface staining was used to assess B cell depletion efficacy by flow cytometry. Compared with the PBS treatment group (no treatment group), the two CD20 T cell conjugates induced effective and almost complete B cell depletion efficacy in blood (32A), spleen (32B) and bone marrow (32C). DETAILED DESCRIPTION

[0051] The present disclosure generally relates to binding proteins, which contain antigen binding sites, T cell receptor binding sites and T cell costimulatory molecule binding sites. The present disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The present disclosure further relates to methods for treating disorders or diseases using such binding proteins.

[0052] The binding proteins disclosed herein preferentially bind to CD8+T cells. Due to the preferential binding to CD8+T cells, the binding proteins avoid engaging with tumor-promoting T cells (such as Treg, Th2 and Th17 cells), and avoid engaging with CD4+T cells that produce most cytokines that cause release syndrome (CRS). By reducing the part of activated T cells, the binding proteins disclosed herein reduce CRS. In addition, the CD8+T cells bound by the binding proteins disclosed herein induce a class of immunogenic programmed cell death (called cell pyroptosis). Cell pyroptosis cells are taken up by antigen presenting cells, and tumor-specific T cell responses can be further driven.

[0053] It should be understood that the specific aspects of the disclosure described herein are not limited to the specific aspects presented and may vary. It should also be understood that the terms used herein are only used for the purpose of describing specific aspects and are not intended to be limiting unless specifically defined herein. In addition, as will be appreciated by those skilled in the art, the specific aspects disclosed herein may be combined with other aspects disclosed herein without limitation.

[0054] Unless otherwise indicated or otherwise apparent from the context and understanding of one of ordinary skill in the art, the values ​​herein expressed as ranges in the various aspects of the present disclosure may take on any specific value or sub-range within the stated range, to the tenth of the unit of the lower limit of that range, unless the context clearly indicates otherwise.

[0055] Throughout this disclosure, unless the context clearly indicates otherwise, the terms "comprise" and "include" and variations thereof (e.g., "comprises, comprising" and "includes, including") should be understood to mean the inclusion of a stated component, feature, element, or step, or a group of components, features, elements, or steps, but not the exclusion of any other component, feature, element, or step, or a group of components, features, elements, or steps. Any of the terms "comprising," "consisting essentially of," and "consisting of" may be replaced with either of the other two terms while retaining their ordinary meanings.

[0056] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0057] The percentages disclosed herein may vary from the disclosed values ​​by an amount of ±10%, 20%, or 30% and still be within the intended disclosed range.

[0058] As used herein, ranges and amounts may be expressed as "about" a particular value or range. About also includes the exact amount. For example, "about 5%" means "about 5%" and also refers to "5%". The term "about" may also refer to ±10% of a given value or range of values. Thus, for example, about 5% also refers to 4.5%-5.5%.

[0059] As used herein, the terms "or" and "and / or" can be used to describe multiple components that are combined or exclusive of each other. For example, "x, y, and / or z" can refer to "x" alone, "y" alone, "z" alone, "x, y, and z", "(x and y) or z", "x or (y and z)", or "x or y or z".

[0060] As used in accordance with this disclosure, unless otherwise noted, all technical and scientific terms should be understood to have the same meaning as commonly understood by one of ordinary skill in the art. Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

[0061] As used herein, the term "binding protein" refers to a non-naturally occurring (or recombinant) molecule comprising multiple polypeptide chains that form at least one antigen binding site.

[0062] A "recombinant" molecule is one that is prepared, expressed, produced or isolated by recombinant DNA technology methods.

[0063] As used herein, the term "antibody" refers to a protein that can recognize and specifically bind to an antigen. Ordinary or conventional mammalian antibodies contain tetramers, which are typically composed of two pairs of identical polypeptide chains, each pair consisting of a "light" chain (typically having a molecular weight of about 25kDa) and a "heavy" chain (typically having a molecular weight of about 50-70kDa). As used herein, the terms "heavy chain" and "light chain" refer to any immunoglobulin polypeptide having sufficient variable domain sequences to confer specificity to a target antigen. The amino terminal portion of each light chain and heavy chain typically includes a variable domain of about 100 to 110 or more amino acids that are typically responsible for antigen recognition. If the antibody is derived from a non-human source, the variable domain can be subjected to further protein engineering to humanize the framework region. The carboxyl terminal portion of each chain typically defines a constant domain responsible for effector function. Therefore, in naturally occurring antibodies, a full-length heavy chain immunoglobulin polypeptide includes a variable domain (V H ) and three constant domains (C H1 , C H2 and C H3 ) and C H1 and C H2 The hinge region between the H The domain is located at the amino terminus of the polypeptide and the C H3The variable domain is located at the carboxyl terminus, and the full-length light chain immunoglobulin polypeptide includes the variable domain (V L ) and constant domain (C L ), where V L The domain is located at the amino terminus of the polypeptide and the C L The domain is located at the carboxyl terminus.

[0064] In full-length light chain and heavy chain, variable domain and constant domain are typically connected by about 12 or more amino acid " J " region, wherein heavy chain also comprises about 10 or more amino acid " D " region.The variable region of each light / heavy chain pair typically forms antigen binding site.The variable domain of naturally occurring antibody typically exhibits the same general structure of relatively conservative framework region (FR) connected by three hypervariable regions (also referred to as complementary determining region or CDR).The CDR from each pair of two chains is typically compared by framework region, and this can make it possible to combine with specific epitope.From amino-terminal to carboxyl-terminal, both light chain and heavy chain variable domain typically comprise domain FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4.

[0065] An "antigen-binding fragment thereof" refers to at least the smallest portion of an antibody that is capable of binding to a given antigen that the antibody targets, such as, in the case of a typical antibody produced by a B cell, a heavy chain (V H ) variable domain and light chain (V L ) at least some of the complementarity determining regions (CDRs) of the variable domains of the antibody or its antigen-binding fragment can be or be derived from a polyclonal antibody, a monoclonal antibody, a human antibody, a humanized antibody, or a chimeric antibody, a single chain antibody, an epitope binding fragment, for example, Fab, Fab' and F(ab')2, Fd, Fv, a single chain Fv (scFv), a single chain antibody, a disulfide-linked Fv (sdFv), a V domain comprising alone or in combination with a portion of an opposing domain. L or V H A domain (e.g., the entire V L domains and partial V domains having one, two or three CDRs H domain), and fragments produced by Fab expression libraries. ScFv molecules are known in the art and are described, for example, in U.S. Pat. No. 5,892,019.

[0066] As used herein, the term "native Fc" refers to a molecule comprising a sequence of a non-antigen binding fragment caused by antibody digestion or produced by other methods, which is in monomeric or multimeric form, and may contain a hinge region. The original immunoglobulin source of native Fc is preferably human origin, and may be any immunoglobulin. The native Fc molecule is composed of monomeric polypeptides that can be connected to dimer or multimeric form by covalent (i.e., disulfide bonds) and non-covalent association. The number range of the intermolecular disulfide bonds between the monomer subunits of the native Fc molecule is from 1 to 4, depending on class (e.g., IgG, IgA and IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgA1 and IgGA2). An example of native Fc is a disulfide bonded dimer caused by papain digestion of IgG. As used herein, the term "native Fc" is general for monomeric, dimer and multimeric forms.

[0067] As used herein, the term "Fc variant" refers to a molecule or sequence modified from a native Fc but still comprising a binding site for a salvage receptor FcRn (neonatal Fc receptor). Exemplary Fc variants and their interactions with salvage receptors are known in the art. Thus, the term "Fc variant" may include a molecule or sequence humanized from a non-human native Fc. In addition, a native Fc comprises an area that can be removed or mutated to produce an Fc variant to alter certain residues, which provide structural features or biological activities that are not required by the binding protein of the present disclosure. Thus, the term "Fc variant" includes a molecule or sequence that lacks one or more native Fc sites or residues, or wherein one or more Fc sites or residues have been modified, which Fc sites or residues affect or participate in: (1) disulfide bond formation, (2) incompatibility with a selected host cell, (3) N-terminal heterogeneity after expression in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a salvage receptor, or (7) antibody-dependent cellular cytotoxicity (ADCC).

[0068] As used herein, the term "Fc" encompasses native Fc and Fc variants as defined above. Like Fc variants and native Fc molecules, the term "Fc" includes molecules in monomeric or multimeric form that are digested from whole antibodies or produced by other methods.

[0069] Binding proteins encompassed by the present disclosure can be or derived from any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecules.

[0070] As used herein, the term "antigen" or "target antigen" refers to a molecule or a portion of a molecule that can be recognized and bound by the antigen binding portion of the binding protein of the present disclosure. The target antigen can be used in an animal to produce an antibody that can bind to an epitope of the antigen. The target antigen can have one or more epitopes. For each target antigen recognized by the antigen binding portion of the binding protein, the antigen binding portion can compete with the intact antibody that recognizes the target antigen.

[0071] The term "antigen binding site" as used herein refers to a site produced on the surface of a binding protein of the present disclosure at which an antigen or an epitope on an antigen is bound.

[0072] The term "linker" as used herein refers to one or more amino acid residues inserted between the domains of the binding protein of the present disclosure. For example, the linker can be inserted between the domains at the sequence level. The precise position of the domain transition can be determined by locating peptide segments that do not form secondary structural elements (such as β-sheets or α-helices), as demonstrated by experimental data or as can be assumed by modeling or secondary structure prediction techniques. Because natural linkers are typically found between immunoglobulin domains, linkers may or may not be needed depending on the position of the termination and start residues of the selected protein fusion.

[0073] As used herein, the term "polynucleotide" includes single nucleic acids as well as multiple nucleic acids, and refers to isolated nucleic acid molecules or constructs, such as messenger RNA (mRNA) or plasmid DNA (pDNA). The term "nucleic acid" includes any nucleic acid type, such as DNA or RNA.

[0074] As used herein, the term "vector" may refer to a nucleic acid molecule introduced into a host cell, thereby producing a transformed host cell. A vector may include a nucleic acid sequence that allows it to replicate in a host cell, such as an origin of replication. A vector may also include one or more selectable marker genes and other genetic elements known in the art. Specific types of vectors contemplated herein may be associated with or incorporated into a virus to promote cell transformation.

[0075] As used herein, the term "treat / treatment / treatment of" refers to reducing disease pathology, reducing or eliminating disease symptoms, promoting improved survival, and / or alleviating discomfort. For example, treatment can refer to the ability of a therapy to reduce disease symptoms, signs, or causes when administered to a subject. Treatment also refers to alleviating or reducing at least one clinical symptom and / or inhibiting or delaying the progression of a condition and / or preventing or delaying the onset of a disease or disorder.

[0076] As used herein, the term "administration" or "administering" refers to providing, contacting and / or delivering a binding protein by any appropriate route to achieve a desired effect. Administration may include, but is not limited to, oral, sublingual, parenteral (e.g., intravenous, subcutaneous, intradermal, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional or intracranial injection), transdermal, topical, buccal, rectal, vaginal, nasal, ocular, via inhalation, and implants.

[0077] As used herein, the term "subject", "individual" or "patient" refers to any subject, particularly a mammalian subject, for whom diagnosis, prognosis or therapy is desired. Mammalian subjects include, for example, humans, non-human primates, dogs, cats, guinea pigs, rabbits, rats, mice, horses, cows, bears, etc.

[0078] As used herein, the term "effective amount" or "therapeutically effective amount" of an administered therapeutic substance (such as a binding protein) is an amount sufficient to carry out a particular stated or intended purpose, such as treating cancer. An "effective amount" can be determined empirically in a routine manner according to the stated purpose.

[0079] The term "pharmaceutical composition" as used herein refers to a compound or composition that can induce a desired therapeutic effect when appropriately administered to a subject. In some aspects, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the binding protein of the present disclosure. As used herein, the term "pharmaceutically acceptable carrier" or "physiologically acceptable carrier" refers to one or more formulation materials suitable for completing or enhancing the delivery of one or more binding proteins of the present disclosure.

[0080] In some aspects, the binding proteins disclosed herein can be formulated into pharmaceutical compositions together with pharmaceutically acceptable carriers, excipients or stabilizers. In some aspects, such pharmaceutical compositions are suitable for administration to humans or non-human animals via any one or more routes of administration using methods known in the art. The term "pharmaceutically acceptable carrier" refers to one or more non-toxic materials that do not interfere with the effectiveness of the biological activity of the active ingredient. Such preparations can conventionally contain salts, buffers, preservatives, compatible carriers, and optionally other therapeutic agents. Such pharmaceutically acceptable preparations can also contain compatible solid or liquid fillers, diluents or encapsulated materials suitable for administration to humans. Other envisioned carriers, excipients, and / or additives that can be used in the formulations described herein include: for example, flavorings, antimicrobial agents, sweeteners, antioxidants, antistatic agents, lipids, protein excipients (such as serum albumin, gelatin, casein), salt-forming counterions (such as sodium), etc. These and additional known pharmaceutical carriers, excipients and / or additives suitable for use in the formulations described herein are known in the art, for example, as listed in "Remington: The Science & Practice of Pharmacy," 21st ed., Lippincott Williams & Wilkins, (2005) and in "Physician's Desk Reference," 60th ed., Medical Economics, Montvale, NJ (2005). A pharmaceutically acceptable carrier may be selected to be suitable for the desired or required mode of administration, solubility and / or stability.

[0081] In some aspects, provided herein are binding proteins comprising two tumor associated antigen (TAA) binding sites. In some aspects, the tumor associated antigen (TAA) is cluster of differentiation 20 (CD20). CD20 is involved in Ca ++ Channel formation, B cell activation and proliferation of transmembrane proteins. CD20 is a membrane-embedded surface molecule that plays a role in B cell development and differentiation into plasma cells. In some aspects, the binding protein comprises a fragment of rituximab (see, e.g., U.S. Patent No. 5,736,137).

[0082] In some aspects, provided herein are binding proteins comprising a T cell receptor (TCR) binding site. TCR comprises a heterodimer comprising a highly variable α chain and a β chain. The multi-component complex of TCR comprises a CD3 co-receptor, which plays an important role in activating T cells.

[0083] In some aspects, provided herein is a binding protein comprising a T cell costimulatory molecule binding site.Costimulatory molecules include costimulatory domains that can enhance or regulate the response of immune effector cells.Costimulatory domains may include, for example, one or more sequences from CD3ζ (or CD3z), CD28, CD137 (4-1BB), OX-40, ICOS, CD27, GITR, CD2, IL-2Rβ and MyD88 / CD40. In some aspects, the T cell costimulatory molecule is CD8. In some aspects, the T cell costimulatory molecule is CD137 (4-1BB).

[0084] Some aspects described herein provide a binding protein comprising four polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the first and second polypeptide chains have a structure represented by the following formula: L -C L ; and the third polypeptide chain has a structure represented by the following formula: V H1 -C H1- V H2 -Fc; and the fourth polypeptide chain has a structure represented by the following formula: V H1 -C H1 -V H3 -Fc; where V L It is the immunoglobulin light chain variable domain that specifically binds to tumor-associated antigens; V H1 It is an immunoglobulin heavy chain variable domain that specifically binds to tumor-associated antigens; C L It is the constant domain of immunoglobulin light chain that specifically binds to tumor-associated antigens; C H1 It is the constant domain of the immunoglobulin CH1 heavy chain that specifically binds to tumor-associated antigens; V H2 V is the heavy chain variable domain that specifically binds to the T cell receptor; H3 It is the heavy chain variable domain that specifically binds to T cell co-stimulatory molecules; and Fc is the immunoglobulin hinge region and C H2 and C H3 Immunoglobulin heavy chain constant domain.

[0085] Some aspects described herein provide a binding protein comprising four polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein two polypeptide chains have a structure represented by the following formula: L -C L And the two polypeptide chains have the structure represented by the following formula: III-V H1 -C H1- V H2 -Fc-II2; wherein: VL It is the immunoglobulin light chain variable domain that specifically binds to tumor-associated antigens; V H1 It is an immunoglobulin heavy chain variable domain that specifically binds to tumor-associated antigens; C L It is the constant domain of immunoglobulin light chain that specifically binds to tumor-associated antigens; C H1 It is the constant domain of the immunoglobulin CH1 heavy chain that specifically binds to tumor-associated antigens; V H2 It is the heavy chain variable domain that specifically binds to the T cell receptor; Fc is the hinge region and C H2 and C H3 An immunoglobulin heavy chain constant domain; III1 and II2 are each independently a heavy chain variable domain that specifically binds to a T cell co-stimulatory molecule or are absent; wherein at least one of III1 and II2 is a heavy chain variable domain that specifically binds to a T cell co-stimulatory molecule.

[0086] Some aspects described herein provide a binding protein comprising four polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein two polypeptide chains have a structure represented by the following formula: III-V L -C L II2; and the two polypeptide chains have a structure represented by the following formula: V H1 -C H1- V H2 -Fc; where: V L It is the immunoglobulin light chain variable domain that specifically binds to tumor-associated antigens; V H1 It is an immunoglobulin heavy chain variable domain that specifically binds to tumor-associated antigens; C L It is the constant domain of immunoglobulin light chain that specifically binds to tumor-associated antigens; C H1 It is the constant domain of the immunoglobulin CH1 heavy chain that specifically binds to tumor-associated antigens; V H2 It is the heavy chain variable domain that specifically binds to the T cell receptor; Fc is the hinge region and C H2 and C H3 An immunoglobulin heavy chain constant domain; III1 and II2 are each independently a heavy chain variable domain that specifically binds to a T cell co-stimulatory molecule or are absent; wherein at least one of III1 and II2 is a heavy chain variable domain that specifically binds to a T cell co-stimulatory molecule.

[0087] Some aspects described herein provide a binding protein comprising four polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein two polypeptide chains have a structure represented by the following formula: L-C L And a polypeptide chain has a structure represented by the following formula: H1 -C H1- Fc; and one polypeptide chain has a structure represented by the following formula: V H2 -V H3- Fc; where: V L It is the immunoglobulin light chain variable domain that specifically binds to tumor-associated antigens; V H1 It is an immunoglobulin heavy chain variable domain that specifically binds to tumor-associated antigens; C L It is the constant domain of immunoglobulin light chain that specifically binds to tumor-associated antigens; C H1 It is the constant domain of the immunoglobulin CH1 heavy chain that specifically binds to tumor-associated antigens; V H2 It is the heavy chain variable domain that specifically binds to T cell co-stimulatory molecules; V H3 It is the heavy chain variable domain that specifically binds to the T cell receptor binding site; Fc is the immunoglobulin hinge region and C H2 and C H3 Immunoglobulin heavy chain constant domain.

[0088] Some aspects described herein provide a binding protein comprising three polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the first polypeptide chain has a structure represented by the following formula: L -C L ; and the second polypeptide chain has a structure represented by the following formula: V H1 -C H1- V H2 -Fc; and the third polypeptide chain has a structure represented by the following formula: V H1 -V H3 -Fc; where: V L It is the immunoglobulin light chain variable domain that specifically binds to tumor-associated antigens; V H1 It is an immunoglobulin heavy chain variable domain that specifically binds to tumor-associated antigens; C L It is the constant domain of immunoglobulin light chain that specifically binds to tumor-associated antigens; C H1 It is the constant domain of the immunoglobulin CH1 heavy chain that specifically binds to tumor-associated antigens; V H2 V is the heavy chain variable domain that specifically binds to the T cell receptor; H3 is a heavy chain variable domain that specifically binds to T cell co-stimulatory molecules; and Fc is C H2 and C H3 Immunoglobulin heavy chain constant domain.

[0089] In some aspects, the heavy chain variable domain that specifically binds to T cell costimulatory molecules is an immunoglobulin heavy chain variable domain. In some aspects, the heavy chain variable domain that specifically binds to T cell costimulatory molecules is a single domain sequence. In a particular aspect, the heavy chain variable domain that specifically binds to T cell costimulatory molecules is a nanobody. In a particular aspect, the heavy chain variable domain that specifically binds to T cell costimulatory molecules is a camelid. In a particular aspect, the heavy chain variable domain that specifically binds to T cell costimulatory molecules is a single domain variable neoantigen receptor.

[0090] In some aspects, the heavy chain variable domain that specifically binds to the T cell receptor binding site is an immunoglobulin heavy chain variable domain. In some aspects, the heavy chain variable domain that specifically binds to the T cell receptor binding site is a single domain sequence. In a particular aspect, the heavy chain variable domain that specifically binds to the T cell receptor binding site is a nanobody. In a particular aspect, the heavy chain variable domain that specifically binds to the T cell receptor binding site is a camelid. In a particular aspect, the heavy chain variable domain that specifically binds to the T cell receptor binding site is a single domain variable new antigen receptor.

[0091] In some aspects, the Fc of the binding protein is from an IgG antibody, such as IgG1, IgG2, IgG3, IgA1, and IgGA2.

[0092] In some aspects, the binding protein comprises a linker. The identity and sequence of the amino acid residues in the linker can vary depending on the type of secondary structure element that needs to be achieved. For example, glycine, serine, and alanine are best for linkers with maximum flexibility. If a more rigid and extended linker is required, some combinations of glycine, proline, threonine, and serine are useful. Any amino acid residue can be considered as a linker combined with one or more other amino acid residues, which can be the same or different from the first amino acid residue, thereby constructing a larger peptide linker when necessary depending on the desired properties. In some aspects, the binding protein comprises L1, C located on the third polypeptide chain, and L2. H1 and V H2 The linker between L2 and V on the third polypeptide chain H2 and a linker between the Fc, wherein L1 and L2 are each independently a linker or are absent. In some aspects, the binding protein comprises L3, a C located on the fourth polypeptide chain H1 and V H3 The linker between L4 and V on the fourth polypeptide chain H3A linker between Fc and Fc, wherein L3 and L4 are each independently a linker or do not exist. In some aspects, L1, L2, L3 and L4 are each independently a linker or do not exist. In some aspects, the linker comprises the amino acid sequence TGGS (SEQ ID NO: 46). In some aspects, the linker comprises the amino acid sequence GGGGS (SEQ ID NO: 47). In some aspects, the linker comprises the amino acid sequence AAAYPYDVPDYGSGEGTSTGSGGSGGSGGA (SEQ ID NO: 48). In some aspects, the linker further comprises a hemagglutinin tag.

[0093] In some aspects, the binding protein comprises H1, a C H1 and V H2 The immunoglobulin hinge region between H2 and the V H2 and an immunoglobulin hinge region between the Fc, wherein H1 and H2 are each independently an immunoglobulin hinge region or are absent. In some aspects, the binding protein comprises H3, a C H1 and V H3 The immunoglobulin hinge region between H4 and the V H3 and an immunoglobulin hinge region between the Fc, wherein H3 and H4 are each independently an immunoglobulin hinge region or are absent. In some aspects, H1, H2, H3 and H4 are each independently an immunoglobulin hinge region or are absent.

[0094] In some aspects, the binding protein comprises a first and a second polypeptide chain having a structure represented by the formula:

[0095] V L -C L

[0096] and a third polypeptide chain having a structure represented by the following formula:

[0097] V H1 -C H1 -H1-L1-V H2 -H2-L2-Fc

[0098] and a fourth polypeptide chain having a structure represented by the following formula:

[0099] V H1 -C H1 -H3-L3-V H3 -H4-L4-Fc.

[0100] In other aspects, the binding protein comprises a first polypeptide chain having a structure represented by the following formula:

[0101] V L -C L

[0102] and a second polypeptide chain having a structure represented by the following formula:

[0103] V H1 -C H1 -H1-L1-V H2 -H2-L2-Fc

[0104] and a third polypeptide chain having a structure represented by the following formula:

[0105] V H1 -H3-L3-V H3 -H4-L4-Fc.

[0106] In other aspects, the binding protein comprises two polypeptide chains having a structure represented by the following formula:

[0107] II1-V L -C L -II2;

[0108] and two polypeptide chains having structures represented by the following formula:

[0109] V H1 -C H1- V H2 -Fc.

[0110] In other aspects, the binding protein comprises a first polypeptide chain having a structure represented by the following formula:

[0111] V L -C L

[0112] and a second polypeptide chain having a structure represented by the following formula:

[0113] V H1 -C H1- V H2 -Fc

[0114] and a third polypeptide chain having a structure represented by the following formula:

[0115] V H1 -V H3 -Fc.

[0116] In some aspects, the binding protein comprises four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise

[0117] (a) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3;

[0118] (b) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 4;

[0119] (c) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 9 and SEQ ID NO: 10;

[0120] (d) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 11 and SEQ ID NO: 12;

[0121] (e) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 13 and SEQ ID NO: 14;

[0122] (f) amino acids of the sequences of SEQ ID NO: 1 and SEQ ID NO: 19;

[0123] (g) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 22 and SEQ ID NO: 23;

[0124] (h) amino acids of the sequences of SEQ ID NO:29 and SEQ ID NO:30;

[0125] (i) amino acids of the sequences of SEQ ID NO:31 and SEQ ID NO:32;

[0126] (j) amino acids of the sequences of SEQ ID NO:33 and SEQ ID NO:34;

[0127] (k) amino acids of the sequences of SEQ ID NO:35 and SEQ ID NO:36; or

[0128] (l) Amino acids of the sequences of SEQ ID NO:37 and SEQ ID NO:38.

[0129] In some aspects, the binding protein comprises three or four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise

[0130] (a) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3;

[0131] (b) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 4;

[0132] (c) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 9 and SEQ ID NO: 10;

[0133] (d) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 11 and SEQ ID NO: 12;

[0134] (e) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 13 and SEQ ID NO: 14;

[0135] (f) amino acids of the sequences of SEQ ID NO: 1 and SEQ ID NO: 19;

[0136] (g) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 22 and SEQ ID NO: 23;

[0137] (h) amino acids of the sequences of SEQ ID NO:29 and SEQ ID NO:30;

[0138] (i) amino acids of the sequences of SEQ ID NO:31 and SEQ ID NO:32;

[0139] (j) amino acids of the sequences of SEQ ID NO:33 and SEQ ID NO:34;

[0140] (k) amino acids of the sequences of SEQ ID NO:35 and SEQ ID NO:36;

[0141] (1) amino acids of the sequences of SEQ ID NO:37 and SEQ ID NO:38;

[0142] (m) amino acids of the sequences of SEQ ID NO:39 and SEQ ID NO:40;

[0143] (n) amino acids of the sequences of SEQ ID NO:41 and SEQ ID NO:42; or

[0144] (o) Amino acids of the sequences of SEQ ID NO:45 and SEQ ID NO:54.

[0145] In some aspects, the binding protein comprises three polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise amino acids of the sequences of SEQ ID NO: 43, SEQ ID NO: 44, and SEQ ID NO: 45, or (q) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 11, and SEQ ID NO: 12. In one embodiment, the binding protein comprises three polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, comprising amino acids of the sequences of SEQ ID NO: 43, SEQ ID NO: 44, and SEQ ID NO: 45.

[0146] In some aspects, provided herein are binding proteins comprising four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise an amino acid sequence having at least 80%, or at least 90%, or at least 95%, or at least 99% sequence identity with any one of the amino acid sequences shown in SEQ ID NO: 1-56. In some aspects, provided herein are binding proteins comprising four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise an amino acid sequence having at least 80%, or at least 90%, or at least 95%, or at least 99% sequence identity with any one of the amino acid sequences shown in SEQ ID NO: 1-42. In some aspects, provided herein are binding proteins comprising three polypeptide chains, which form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise an amino acid sequence having at least 80%, or at least 90%, or at least 95%, or at least 99% sequence identity with any one of the amino acid sequences shown in SEQ ID NO: 1-56. In some aspects, provided herein are binding proteins comprising three polypeptide chains, which form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise an amino acid sequence having at least 80%, or at least 90%, or at least 95%, or at least 99% sequence identity with any one of the amino acid sequences shown in SEQ ID NO: 1-42.

[0147] In particular aspects, provided herein are amino acid sequences having conservative variants wherein up to 10, up to 8, up to 5, and up to 3 amino acids are substituted with amino acids having similar or analogous properties compared to the amino acid sequences of the sequences disclosed herein.

[0148] The binding proteins of the disclosure can be prepared using domains or sequences obtained or derived from any human or non-human antibody (including, for example, human, murine or humanized antibodies).

[0149] Some aspects of the present disclosure relate to an isolated nucleic acid sequence encoding a binding protein as described herein. The isolated nucleic acid sequence can be included in a vector.

[0150] In some aspects, the methods disclosed herein relate to treating cancer in a subject by administering an effective amount of a binding protein. The present disclosure also provides a therapeutically effective amount of a binding protein for use in treating cancer in a subject. In one embodiment, a method for treating an inflammatory disease in a subject by administering an effective amount of a binding protein is provided. In one embodiment, a binding protein or a pharmaceutical composition comprising the binding protein and a pharmaceutically acceptable carrier is provided, which is used as a medicament. In another embodiment, a binding protein or a pharmaceutical composition comprising the binding protein and a pharmaceutically acceptable carrier is provided, which is used in the treatment of cancer. In another embodiment, a binding protein or a pharmaceutical composition comprising the binding protein and a pharmaceutically acceptable carrier is provided, which is used in the treatment of inflammatory diseases. In another embodiment, a binding protein or a pharmaceutical composition comprising the binding protein and a pharmaceutically acceptable carrier is provided for use in the manufacture of a medicament for use in the treatment of an inflammatory disease. In a further embodiment, a binding protein or a pharmaceutical composition comprising the binding protein and a pharmaceutically acceptable carrier is provided for use in the manufacture of a medicament for use in the treatment of a cancer.

[0151] In some aspects, the cancer comprises a B-cell malignancy, which includes chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.

[0152] In some aspects, the method disclosed herein relates to treating an inflammatory disease involving B cells in a subject by administering an effective amount of a binding protein. The present disclosure also provides a therapeutically effective amount of a binding protein for use in treating an inflammatory disease involving B cells in a subject. In the method of treatment disclosed herein, the binding protein can preferentially activate a T cell subset of the subject. The T cell subset can be a CD8+T cell. Compared with CD4 T cells, the CD8+T cells can be preferentially activated. The preferential activation of CD8+T cells reduces engagement with tumor-promoting T cells and CD4+T cells (most of the cytokines that these cells produce cause release syndrome (CRS)). In addition, the preferential engagement of CD8+T cells induces cell pyroptosis.

[0153] The activation of T cells by the method of the present disclosure can be determined by measuring the percentage of surface interleukin-2 receptor alpha chain positive (CD25+) T cells. The percentage of CD8 T cells in surface CD25+T cells can be higher than the percentage of CD4 T cells in surface CD25+T cells. In certain aspects, the activation of T cells can be determined by the percentage of CD69+ / CD25+T cells. In certain aspects, the activation of T cells can be determined by measuring the level of cytokines released by activated T cells.

[0154] Relative to the effect produced by bispecific T cell engagers (BiTE) previously known in the art, the treatment method disclosed herein can result in reduced engagement of regulatory T cells (Treg), increased cytolytic activity, and / or reduced incidence of cytokine release syndrome (CRS). The disclosure also provides a therapeutically effective amount of binding proteins for use in reducing engagement of regulatory T cells (Treg), increasing cytolytic activity, and / or reducing the incidence of cytokine release syndrome (CRS) (relative to the effect produced by bispecific T cell engagers (BiTE) previously known in the art).

[0155] In view of the present disclosure, the methods and compositions described herein can be configured by one of ordinary skill in the art to meet desired needs.

[0156] In some aspects, the inflammatory disease or an inflammatory disease involving B cells is selected from rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, pemphigus, deep lupus, scleroderma, discoid lupus erythematosus, systemic lupus erythematosus, Sjögren's syndrome, atopic dermatitis, and allergic contact dermatitis.

[0157] Examples

[0158] The following examples illustrate specific aspects of the present disclosure and various uses thereof. They are set forth for illustrative purposes only and should not be construed in any way as limiting the scope of the present disclosure.

[0159] Example 1: Binding protein structure and cytolytic and T cell activity

[0160] A novel class of binding proteins is described herein that are engineered to improve safety and enhance efficacy. Multiple binding protein formats were tested to determine the location of the TCR binding domain, the location of the T cell co-stimulatory domain, the size and cleavage of the linker, and the Fc portion to be used. Figure 1 Representative structures of these binding proteins are shown. Figure 2A and Figure 2B As shown, binding proteins MCAZ 6.9 and MCAZ 6.10 were generated to include two CD20 binding sites, a CD8 co-stimulatory binding arm ( Figure 2A) and CD137 binding arm ( Figure 2B ), TCR binding domain and two protease cleavage sites. Similarly, MCAZ 7.1 was generated to include two CD20 binding sites, CD8 co-stimulatory binding arm and TCR binding domain, but not two protease cleavage sites ( Fig. 10A ).

[0161] MCAZ 6.9 and MCAZ 6.10 binding proteins were assessed for in vitro cell lysis of CD20+B cell lines Daudi, Ramos and Raji. The pan-T cells of B cells and purification were incubated with the B cell line with the E:T ratio of 5:1 for 4 days, and % cell lysis was measured by flow cytometry. MCAZ 7.1 was assessed for cell lysis of CD20+B cell lines Toledo, Oci-LY18 and SU-DHL5 (expressing 12420, 20244 and 27152 CD20 antigens / cells respectively). B cell line was subjected to CTV staining and PBMC was incubated with the E:T ratio of 5:1 for 4 days. % cell lysis was measured by flow cytometry.

[0162] MCAZ 6.9, MCAZ 6.10 and MCAZ 7.1 binding proteins induced strong in vitro cytolytic activity ( Figures 3A to 3C , Fig. 10C and 10D ). Cytolysis was associated with efficient T-cell activation, which was biased towards CD8 T cells for MCAZ 6.9 and MCAZ 7.1 ( Figure 4A , 5A , 6 and 10E), and for MCAZ 6.10 has a CD4-biased profile or an equivalent CD4 / CD8 profile ( Figure 4B , 5B and 6).

[0163] To determine the optimal location of the TCR binding domain, MCAZ 88, MCAZ 7.5, and MCAZ 89 were generated with either unique TCR binding domain locations or the absence of a TCR binding domain. MCAZ 88 includes two TCR binding domains at the end of each variable heavy chain domain ( Fig. 7A ), MCAZ 7.5 has a TCR binding domain located in the hinge portion of the binding protein ( Fig. 8A ), while the MCAZ 89 binding protein does not include any TCR binding domain ( Fig. 8A ).

[0164] In order to test the cytolysis of MCAZ 88, the cytolysis of the induction of Raji cell line (CD20+, 85371 antigens / cell) was evaluated. B cells and PBMC were incubated with the B cell line at an E:T ratio of 5:1 for 4 days, and % cytolysis was measured by flow cytometry. The CD4 and CD8 T cell activation profiles of MCAZ88, MCAZ7.5 and MCAZ89 binding proteins were also evaluated by measuring the % and %CD69+ / CD25+ surface expression of surface CD25+ cells. The results show that in the absence of a T cell costimulatory domain, the presence of two TCR binding domains is sufficient to induce cytolysis ( Figure 7B However, both the absence of the TCR binding domain and the location of the TCR binding domain on top of the binding protein lead to nonspecific T cell activation ( Figure 7C , Figure 8B , Figure 8C , Figure 9). Only when the TCR binding domain is in the hinge region of the binding protein does nonspecific T cell activation decrease strongly ( Figure 8B , Figure 8C ).

[0165] Binding proteins MCAZ8.71 and MCAZ 8.81 were generated with two T cell co-stimulatory molecules in unique positions on the binding protein to evaluate the effect of CD8 localization on binding protein function ( Figures 12A to 12B ). Cytolysis was assessed on a CD20+BRaji cell line (expressing 85,000 CD20 antigens / cell). The B cell line was CTV stained and incubated with PBMCs for 4 days at an E:T ratio of 5:1. % Cytolysis was measured by flow cytometry. CD4 and CD8 T cell activation profiles were assessed as % CD25 expressing cells. Despite the different locations of T cell co-stimulatory molecules in the binding protein or the presence of additional T cell co-stimulatory molecules, both MCAZ 8.71 and MCAZ 8.81 showed similar cytolysis ( Figures 12C to 12D ). Cytolysis was associated with effective T cell activation, which was biased towards CD8 T cells for MCAZ 8.71 and MCAZ 8.81 ( Fig.12E ). These results demonstrate that the location of the co-stimulatory molecules within the binding protein is flexible, yet the additional molecules do not increase the potency of the binding protein.

[0166] To test the position of the T cell co-stimulatory domain and the T cell binding domain relative to each other, different orientations of the binding protein were tested. MCAZ 10.3 was generated to include both the CD8 domain and the TCR binding domain on the same polypeptide ( Fig. 10C). The T cell co-stimulatory domain and the T cell binding domain were also tested on separate binding proteins. In particular, MCAZ 8.69 was generated as a binding protein including only the T cell co-stimulatory molecule and MCAZ 8.70 was generated as a binding protein including only the TCR binding domain ( Fig.13A ). Cytolysis was assessed on CD20+B Raji cell lines, namely Toledo, Oci-LY18 and SU-DHL5 cell lines. B cell lines were CTV stained and incubated with PBMCs at an E:T ratio of 5:1 for 4 days. % cytolysis was measured by flow cytometry. CD4 and CD8 T cell activation profiles were assessed as % CD25 expressing cells. The results demonstrate that for cytolysis and T cell activation, the ideal position of the CD8 domain and the TCR binding domain is on separate arms but present in the same binding protein ( Figures 10C to 10E and Figure 13).

[0167] Modified linker lengths were tested to determine the optimal linker for stability and function of the binding protein. MCAZ 7.7 (GGGGSGGGGS) was generated with a modified, longer linker (T) between the CD20 binding domain and the TCR binding domain compared to MCAZ 7.1, which has a linker (T) between the CD20 binding domain and the TCR binding domain. Fig.11A ). MCAZ 10.1 was generated with a more rigid CD8 arm compared to MCAZ7.1. Specifically, the (TGGS (SEQ ID NO: 46)) linker between the CD20 binding domain and the CD8 domain was removed, and the linker between the CD8 domain and the Fc domain was converted from (AAAYPYDVPDYGSGEGTSTGSGGSGGSGGA (SEQ ID NO: 48)) in MCAZ 7.1 to (G) in MCAZ 10.1. Fig.11E). In addition, MCAZ 10.1 was produced, with a missing linker between the CD20 binding domain and the TCR binding domain compared to MCAZ 7.1 with a linker (T), and a shortened linker (G) between the TCR binding domain and the Fc compared to MCAZ 7.1 with a linker (GEGTSTGSGGSGGSGGA (SEQ ID NO: 49)). For MCAZ 7.7, cytolysis was assessed on the CD20+Raji B cell line (expressing 85,000 CD20 antigens / cell). The B cell line was stained with CTV and PBMCs were incubated at an E:T ratio of 5:1 for 4 days. % cytolysis was measured by flow cytometry. For MCAZ 10.1, cytolysis was assessed on the OCI-Ly18 B cell line. The B cell line was stained with CTV and PBMCs were incubated at an E:T ratio of 5:1 for 3 days. % cytolysis was measured by flow cytometry. T cell activation profiles were assessed with %CD25 expressing cells. For MCAZ7.7, nonspecific and specific T cell activation was assessed by plate binding of the binding protein and addition of 1.5e5 purified T cells in the absence of tumor cells and associated proteases. After 48 h of incubation, nonspecific CD8 and CD4 T cell activation levels were assessed by flow cytometry as % CD69+ / CD25+ surface expression. Compared to MCZA 7.1, the modified longer linker in MCZA7.7 increased the level of cytolysis, however, the longer linker in MCZA 7.7 resulted in nonspecific T cell activation. Removal of the linker in MCAZ 10.1 inhibited the function of the binding protein and resulted in minimal cytolysis and T cell activation.

[0168] Produced as Fig.15A The various binding proteins shown were tested with different non-cleavable Fc regions including IgG1 (MCAZ 11.1), IgG2 (MCAZ 11.2), IgG3 (MCAZ 11.3), IgG4 (MCAZ 11.5), mutated IgG1 (MCAZ 11.5), IgD (MCAZ 11.6) and IgA1 (MCAZ 11.7). The cytolytic activity of the binding proteins was tested on the OCI-Ly18 B cell line (with PBMC at an E:T ratio of 5:1) at 72h. The CD8 and CD4 T cell activation profiles were assessed by measuring the % of surface CD25+T cells. The binding proteins with IgG Fc regions were most effective in cytolysis and inducing T cell activation ( Figures 15B to 15D ).

[0169] Based on the above experiments, it was found that a format such as that shown by MCAZ 7.1 provides optimal cell lysis and induces T cell activation.

[0170] Example 2: In vitro testing of binding proteins compared to a broad CD3 x CD20 bivalent conjugate

[0171] The activity of the novel binding proteins disclosed herein was compared to a broad range of CD20 bivalent binders that have been established to be effective in clinical therapy.

[0172] The activity of MCAZ 7.1 variants and a broad CD3 x CD20 bivalent conjugate was compared ( Fig.16A ). In particular, the variant includes a linker between the CD20 binding domain and the CD8 domain and a linker between the CD20 binding domain and the TCR domain (TGGS (SEQ ID NO: 46)), as well as a linker between the CD8 domain and the Fc region and between the TCR domain and the Fc domain (GGGGS (SEQ ID NO: 47)). The binding protein and the bivalent conjugate were incubated with target CD20+ cells for 72 h (at an E:T ratio of 5:1, with PBMCs from healthy donors). The MCAZ7.1 variant induced similar E max cytolysis (approximately pMEC50), but had a distinct and significant CD8-biased activation profile ( Fig. 16B ).

[0173] Compare the combination of MCAZ 7.1 variants and CD3xCD20 bivalent conjugates with CD8 T cells.On CD20+ tumor B cell line (OCI-Ly-18), on purified CD4 and CD8 T cells from PBMC of healthy donors, MCAZ7.1 variant binding spectrum is evaluated.In order to evaluate the B cell induced by CD3xCD20 bivalent conjugates: T cell association, OCI-Ly18 tumor cells are CTV stained and mixed with pan T cells from healthy donors at a ratio of 1: 1, and incubated at room temperature for 1h.Then after incubation with MCAZ7.1 variants and CD3xCD20 bivalent conjugates, after CD4 and CD8 T cell staining, the % of CD8-B cell conjugates and CD4-T cell conjugates are evaluated by flow cytometry. The results demonstrated that the MCAZ7.1 variant exhibited strong binding to CD8 T cells and induced preferential association of CD20+ tumor cells with CD8 T cells compared to the therapeutically effective broad CD3xCD20 bivalent conjugate ( Figures 17A to 17F ).

[0174] The 3D spheroid model was used to determine the cytolytic activity of MCAZ7.1 variants compared with CD3xCD20 bivalent conjugates. The CD20+B cell line (TMD8, 100000 CD20 / cell) expressing GFP was plated in a low adhesion plate for 72h to form a 3D spheroid. Then, purified pan-T cells were added with an E:T ratio of 15:1, and co-incubated for 96h in the absence of conjugates, with TENG0093 or CD3xCD20 bivalent conjugates. GFP+TMD8 cells were quantified using CellinsightCX7HCS platform imager. The variants of MCAZ 7.1 provide effective CD20+ cell killing (comparable to CD3xCD20 bivalent molecules) Fig. 20B ).

[0175] To evaluate the inflammatory cytokine release of the MCAZ7.1 binding protein compared to the CD3xCD20 bivalent conjugate, MCAZ7.1 and CD3xCD20 bivalent conjugates were incubated with OCI-Ly18 B cell line and PBMCs at an E:T ratio of 5:1 for 72 h. The supernatants were harvested and analyzed by multiplex assays to measure the concentrations of the following released pro-inflammatory cytokines: Fig.18A )IL-6, ( Fig.18B )TNF-α、( Fig. 18C )IL-10, Fig.18D )IFN-g, ( Fig.18E )IL-2 and ( Fig.18F ) IL-17A. CD8-specific engagement of MCAZ7.1 provided similar Emax killing of CD20+ tumor cells as the CD3xCD20 bivalent engager, but cytolysis was associated with significantly lower pro-inflammatory cytokine release compared to CD3+ T cell engagement by the CD3xCD20 bivalent engager.

[0176] Example 3: In vivo efficacy in a humanized NSG mouse model of B-cell lymphoma

[0177] The pharmacokinetics of MCAZ 7.1 were evaluated after a single dose. In particular, 0.5 mg / kg of T cell conjugates were injected into NSG mice humanized with pan-T cells, and the systemic concentration of T cell conjugates was measured after 1 h, 6 h, 24 h, 48 h, 72 h, and 168 h. The results showed that MCAZ 7.1 binding protein was stable in vivo ( Fig.21 ).

[0178] To test the efficacy of MCAZ 7.1 binding protein for tumor growth inhibition, pan T cells were transplanted into NSG mice two days before the start of the study. 5e6 OCI-Ly18 CD20+ tumor cell lines were implanted subcutaneously on day 0, and animals were intraperitoneally administered 1 mg / kg of MCAZ7.1 or CD3xCD20 bivalent conjugates on day 2, followed by weekly dosing at the same concentration, as indicated by the gray arrows under the X-axis. MCAZ 7.1 and CD3xCD20 bivalent conjugates showed similar efficacy and complete tumor growth inhibition ( Fig. 22 ).

[0179] To evaluate the in vivo cytokine release of MCAZ 7.1 compared to the CD3xCD20 bivalent conjugate, NSG mice were transplanted with 10e6 PBMCs (ip) followed by irradiation (2.3 Gy), treated with Fc blocker (400 mg / mouse, ip) 48 h later, and treated with 2 mg / kg of OKT3 antibody (ip) or the indicated binding protein at 1 mg / kg (ip) 24 h later. Blood was collected at 6 h and 24 h after injection for evaluation of cytokine concentrations by multiple assays. In vivo cytokine release evaluation in the CRS (cytokine release syndrome) model confirmed that MCAZ 7.1 induced lower cytokine release ( 95% CI 2.0-1.0) compared to the extensive CD3+ T cell engagement induced by the CD3xCD20 bivalent molecule. Figures 23A to 23F ).

[0180] Example 4: In vitro activity of binding proteins on PBMCs from non-Hodgkin's lymphoma donors

[0181] To determine the efficacy of the binding protein in B cell killing and T cell activation, B cell killing was assessed on PBMCs from NHL (DLBCL) donors. MCAZ 7.1 variants were incorporated into PBMCs at various concentrations, and 48 h later, the % B cells of each patient were assessed by flow cytometry. Both the CD8-specific T cell engagers MCAZ 7.1 and MCAZ 7.1 variants showed similar strong CD20+B cell killing on PBMCs from non-Hodgkin's lymphoma donors, and confirmed strong CD8 T cell-biased activation ( Figures 24A to 24F ).

[0182] Based on the various binding protein formats tested, a binding protein with a novel conformation was identified, comprising a TCR binding domain and a T cell co-stimulatory domain on separate arms, using an IgGFc located in the hinge region. This binding protein advantageously has improved cytolytic activity and reduced incidence of cytokine release in vitro and in vivo in the absence of tumor target cells (non-specific T cell activation) and during cytolytic activity in the presence of tumor target cells. In addition, compared to a wide range of CD3 conjugates, the binding formats disclosed herein provide reduced CD4 engagement, including (i) limiting Treg activation and proliferation and limiting potential inhibitory activity to CD8 cytolytic T cells, and (ii) reducing engagement of other CD4 T cell subsets (Th1, Th2, Th9, TH17), all of which have been shown to be associated with drivers of cytokine release syndrome events.

[0183] The aspects described herein appropriately illustratively can be practiced in the absence of any one or more elements, one or more limitations not specifically disclosed herein. The terms and expressions that have been adopted are used as descriptive terms, rather than restrictive, and it is not intended to exclude any equivalents of the features shown and described or parts thereof when using such terms and expressions, but it should be recognized that various modifications can be made within the scope of the claimed aspects. Therefore, it should be understood that although the present invention has been particularly disclosed by aspects, optional features, those skilled in the art can modify and change the concepts disclosed herein, and it is believed that such modifications and variations can be within the scope of these aspects defined by the specification and the appended claims. Although some aspects of the present disclosure may be considered particularly advantageous, it is expected that the present disclosure is not limited to these specific aspects of the present disclosure.

[0184] Unless otherwise indicated or otherwise apparent from the context, a claim or description including "or" between one or more group members is considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or method. The present disclosure includes aspects in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or method. The present disclosure includes aspects in which more than one or all of the group members are present in, employed in, or otherwise relevant to a given product or method.

[0185] In addition, the present disclosure covers all variations, combinations and permutations in which one or more limitations, elements, clauses and descriptive terms from one or more listed claims are introduced into another claim. For example, any claim attached to another claim may be amended to include one or more limitations found in any other claim attached to the same base claim. Where elements are presented as a list (e.g., in Markush group form), each subgroup of elements is also disclosed, and any element may be removed from the group.

[0186] It should be understood that, generally, where the disclosure or aspects of the disclosure are referred to as comprising specific elements and / or features, some aspects of the disclosure or aspects of the disclosure are composed of or substantially composed of such elements and / or features. For the purpose of brevity, those aspects are not particularly set forth in text herein.

[0187]

[0188]

[0189]

[0190]

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198]

[0199]

[0200]

[0201]

[0202]

[0203]

[0204]

[0205]

[0206]

[0207]

[0208]

[0209]

[0210]

[0211]

[0212]

[0213]

[0214]

[0215]

[0216]

[0217]

[0218]

[0219]

[0220]

[0221]

[0222]

[0223]

Claims

1. A binding protein comprising four polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site and a T cell co-stimulatory molecule binding site, wherein the first and second polypeptide chains have a structure represented by the following formula: In L -C L And the third polypeptide chain has a structure represented by the following formula: In H1 -C H1- In H2 -Fc And the fourth polypeptide chain has a structure represented by the following formula: In H1 -C H1 -V H3 -Fc in : V L It is an immunoglobulin light chain variable domain that specifically binds to tumor-associated antigens; V H1 It is an immunoglobulin heavy chain variable domain that specifically binds to tumor-associated antigens; C L It is the constant domain of the immunoglobulin light chain that specifically binds to tumor-associated antigens; C H1 It is the constant domain of the immunoglobulin CH1 heavy chain that specifically binds to tumor-associated antigens; V H2 It is the heavy chain variable domain that specifically binds to the T cell receptor; V H3 is a heavy chain variable domain that specifically binds to a T cell co-stimulatory molecule; and Fc is C H2 and C H3 Immunoglobulin heavy chain constant domain.

2. The binding protein according to claim 1, further comprising L 1 , located on the third polypeptide chain H1 and V H2 The connector between 2 , V located on the third polypeptide chain H2 and the linker between the Fc, wherein L 1 and L 2 Each is independently a linker or absent.

3. The binding protein according to claim 1 or claim 2, further comprising L 3 , located on the fourth polypeptide chain H1 and V H3 The connector between 4 , V located on the fourth polypeptide chain H3 and Fc, wherein L 3 and L 4 Each is independently a linker or absent.

4. The binding protein according to any one of claims 1 to 3, further comprising H 1 , located on the third polypeptide chain H1 and V H2 The immunoglobulin hinge region between 2 , V located on the third polypeptide chain H2 The immunoglobulin hinge region between the Fc 1 and H 2 Each is independently an immunoglobulin hinge region or is absent.

5. The binding protein according to any one of claims 1 to 4, further comprising H 3 , located on the fourth polypeptide chain H1 and V H3 The immunoglobulin hinge region between 4 , V located on the fourth polypeptide chain H3 The immunoglobulin hinge region between the Fc 3 and H 4 Each is independently an immunoglobulin hinge region or is absent.

6. The binding protein of any one of claims 1 to 5, wherein the first and second polypeptide chains have a structure represented by the following formula: In L -C L And the third polypeptide chain has a structure represented by the following formula: In H1 -C H1 -H 1 -L 1 -V H2 -H 2 -L 2 -Fc And the fourth polypeptide chain has a structure represented by the following formula: In H1 -C H1 -H 3 -L 3 -V H3 -H 4 -L 4 -Fc.

7. The binding protein of any one of claims 1-6, wherein the Fc is from an IgG antibody.

8. The binding protein of any one of claims 1-7, wherein the binding protein activates T cells only when bound to a tumor-associated antigen at one or both of the antigen binding sites.

9. The binding protein of any one of claims 1-8, wherein the tumor-associated antigen is CD20.

10. The binding protein of any one of claims 1-9, wherein the T cell co-stimulatory molecule is CD8 or CD137.

11. A binding protein comprising four polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site and a T cell co-stimulatory molecule binding site, wherein two polypeptide chains have a structure represented by the following formula: In L -C L And the two polypeptide chains have a structure represented by the following formula: II 1 -V H1 -C H1- In H2 -Fc-II 2 ; in : V L It is an immunoglobulin light chain variable domain that specifically binds to tumor-associated antigens; V H1 It is an immunoglobulin heavy chain variable domain that specifically binds to tumor-associated antigens; C L It is the constant domain of the immunoglobulin light chain that specifically binds to tumor-associated antigens; C H1 It is the constant domain of the immunoglobulin CH1 heavy chain that specifically binds to tumor-associated antigens; V H2 It is the heavy chain variable domain that specifically binds to the T cell receptor; Fc is C H2 and C H3 Immunoglobulin heavy chain constant domain; II 1 and II 2 Each independently is a heavy chain variable domain that specifically binds to a T cell co-stimulatory molecule or is absent; II 1 and II 2 At least one of the heavy chain variable domains specifically binds to a T cell co-stimulatory molecule.

12. A binding protein comprising four polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site and a T cell co-stimulatory molecule binding site, wherein two polypeptide chains have a structure represented by the following formula: II 1 -V L -C L -II 2 4 And the two polypeptide chains have a structure represented by the following formula: In H1 -C H1- In H2 -Fc; in : V L It is an immunoglobulin light chain variable domain that specifically binds to tumor-associated antigens; V H1 It is an immunoglobulin heavy chain variable domain that specifically binds to tumor-associated antigens; C L It is the constant domain of the immunoglobulin light chain that specifically binds to tumor-associated antigens; C H1 It is the constant domain of the immunoglobulin CH1 heavy chain that specifically binds to tumor-associated antigens; V H2 It is the heavy chain variable domain that specifically binds to the T cell receptor; Fc is C H2 and C H3 Immunoglobulin heavy chain constant domain; II 1 and II 2 Each independently is a heavy chain variable domain that specifically binds to a T cell co-stimulatory molecule or is absent; II 1 and II 2 At least one of the heavy chain variable domains specifically binds to a T cell co-stimulatory molecule.

13. A binding protein comprising three polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site and a T cell co-stimulatory molecule binding site, wherein the first polypeptide chain has a structure represented by the following formula: In L -C L And the second polypeptide chain has a structure represented by the following formula: In H1 -C H1- In H2 -Fc And the third polypeptide chain has a structure represented by the following formula: In H1 -V H3 -Fc in : V L It is an immunoglobulin light chain variable domain that specifically binds to tumor-associated antigens; V H1 It is an immunoglobulin heavy chain variable domain that specifically binds to tumor-associated antigens; C L It is the constant domain of the immunoglobulin light chain that specifically binds to tumor-associated antigens; C H1 It is the constant domain of the immunoglobulin CH1 heavy chain that specifically binds to tumor-associated antigens; V H2 It is the heavy chain variable domain that specifically binds to the T cell receptor; V H3 is a heavy chain variable domain that specifically binds to a T cell co-stimulatory molecule; and Fc is C H2 and C H3 Immunoglobulin heavy chain constant domain.

14. The binding protein of any one of claims 11-13, wherein the binding protein activates T cells only when bound to a tumor-associated antigen at one or both of the antigen binding sites.

15. The binding protein of any one of claims 11-14, wherein the tumor-associated antigen is CD20.

16. The binding protein of any one of claims 11-15, wherein the T cell co-stimulatory molecule is CD8 or CD137.

17. A binding protein comprising four polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise (a) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; (b) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 4; (c) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 9 and SEQ ID NO: 10; (d) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 11 and SEQ ID NO: 12; (e) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 13 and SEQ ID NO: 14; (f) amino acids of the sequences of SEQ ID NO: 1 and SEQ ID NO: 19; (g) amino acids of the sequences of SEQ ID NO: 1, SEQ ID NO: 22 and SEQ ID NO: 23; (h) amino acids of the sequences of SEQ ID NO:29 and SEQ ID NO:30; (i) amino acids of the sequences of SEQ ID NO:31 and SEQ ID NO:32; (j) amino acids of the sequences of SEQ ID NO:33 and SEQ ID NO:34; (k) amino acids of the sequences of SEQ ID NO:35 and SEQ ID NO:36; (1) amino acids of the sequences of SEQ ID NO:37 and SEQ ID NO:38; (m) amino acids of the sequences of SEQ ID NO:39 and SEQ ID NO:40; (n) amino acids of the sequences of SEQ ID NO:41 and SEQ ID NO:42; or (o) Amino acids of the sequences of SEQ ID NO:45 and SEQ ID NO:

54.

18. A binding protein comprising three polypeptide chains forming two tumor-associated antigen binding sites, a T cell receptor binding site and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise amino acids of the sequences of SEQ ID NO:43, SEQ ID NO:44 and SEQ ID NO:45, or (q) amino acids of the sequences of SEQ ID NO:1, SEQ ID NO:11 and SEQ ID NO:

12.

19. A pharmaceutical composition comprising the binding protein according to any one of claims 1 to 18, and a pharmaceutically acceptable carrier.

20. An isolated nucleic acid sequence encoding the binding protein of claim 17 or claim 18.

21. A vector comprising the isolated nucleic acid sequence of claim 20.

22. A method for treating cancer, comprising administering an effective amount of the binding protein of any one of claims 1-18 to a subject in need thereof.

23. The method of claim 22, wherein the binding protein preferentially activates a subpopulation of T cells in the subject.

24. The method of claim 22 or 23, wherein the T cell subset is CD8 T cells.

25. The method of any one of claims 22-24, wherein the CD8 T cells are preferentially activated compared to CD4 T cells.

26. The method of claim 23, wherein activation of T cells is determined by measuring the percentage of surface CD25+ T cells.

27. The method of claim 26, wherein the percentage of CD8 T cells among the surface CD25+ T cells is higher than the percentage of CD4 T cells among the surface CD25+ T cells.

28. A method for treating an inflammatory disease, the method comprising administering to a subject in need thereof an effective amount of the binding protein of any one of claims 1-18.

29. The binding protein of any one of claims 1 to 18 or the pharmaceutical composition of claim 19 for use as a medicament.

30. The binding protein of any one of claims 1-18 or the pharmaceutical composition of claim 19 for use in the treatment of cancer.

31. The binding protein of any one of claims 1 to 18 or the pharmaceutical composition of claim 19 for use in the treatment of an inflammatory disease.

32. Use of the binding protein of any one of claims 1 to 18 or the pharmaceutical composition of claim 19 in the manufacture of a medicament for use in the treatment of cancer.

33. Use of the binding protein of any one of claims 1 to 18 or the pharmaceutical composition of claim 19 in the manufacture of a medicament for use in the treatment of an inflammatory disease.